How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,540 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials. Full Text available with Trip Pro

Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials. To systematically evaluate the efficacy and safety of Modified Tongxie Yaofang (M-TXYF) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).Electronic databases including PubMed, Springer Link, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature (CBM), Wanfang (...) , and Chinese Scientific Journals Database (VIP) were conducted from their inception through May 11, 2017 without language restrictions. Primary and secondary outcomes were estimated by 95% confidence intervals (CI). RevMan 5.3 and the Cochrane Collaboration's risk of bias tool were analyzed for this meta-analysis.Twenty-three literatures with a total of 1972 patients were included for the meta-analysis. The overall risk of bias evaluation was low. The pooled odds ratio showed that M-TXYF was significantly

2018 PLoS ONE

22. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Full Text available with Trip Pro

within paediatric pain management. Non-steroidal anti-inflammatory drugs are currently licensed for use in Western countries, however they are not approved for infants under three months old. The main adverse effects include renal impairment and gastrointestinal issues. Common side effects in children include diarrhoea, headache, nausea, constipation, rash, dizziness, and abdominal pain.To assess the analgesic efficacy and adverse events of NSAIDs used to treat chronic non-cancer pain in children (...) % of aspirin participants (low-quality evidence). Secondary outcomesAll seven studies reported adverse events. Participants reporting an adverse event (one or more per person) by drug were: aspirin 85/202; fenoprofen 28/49; ibuprofen 40/45; indomethacin 9/30; ketoprofen 9/30; meloxicam 18/47; naproxen 44/202; and rofecoxib 47/209 (very low-quality evidence).All seven studies reported withdrawals due to adverse events. Participants withdrawn due to an adverse event by drug were: aspirin 16/120; celecoxib 10

2017 Cochrane

23. Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. Full Text available with Trip Pro

Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. To comprehensively evaluate the efficacy and safety of acupuncture combined with Chinese herbal medicine (CHM) in treating irritable bowel syndrome with diarrhea (IBS-D).Relevant randomized controlled trials (RCTs) were systemically retrieved from electronic databases from inception to March 2018, including the Cochrane Central Register of Controlled Trials (CENTRAL (...) ), PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Biological Medical Database (CBM, SinoMed), China Science and Technology Journal Database (VIP), and Wan Fang Data. Meanwhile, pooled estimates, including the 95% confidence interval (CI), were calculated for primary and secondary outcomes of IBS-D patients. Besides, quality of relevant articles was evaluated using the Cochrane Collaboration's risk of bias tool, and the Review Manager 5.3 and Stata12.0 softwares were employed

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

24. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations

. Methods An Expert Panel was convened to update clinical practice guideline recommendations based on a systematic review of the medical literature. Recommendations For patients with high PD-L1 expression (TPS$ 50%) and nonsquamous cell carcinoma (non-SCC), in the absence of contraindications to immune checkpoint therapies, treatment options include: Recommendation1.1. ForpatientswithhighPD-L1expression(TPS$50%),non-SCC,andperformancestatus(PS)0to1, clinicians should offer single-agent pembrolizumab (...) , andPS0 to1,andwhohave contraindicationstoordeclineimmunotherapy, cliniciansshouldoffer standardchemotherapy with platinum-based two-drug combinations as outlined in the 2015 update (Type: evidence based; Evidence quality: high; Strength of recommendation: strong). Recommendation 2.5. For patients with negative (TPS 0%) and low positive (TPS 1% to 49%) PD-L1 expression, non-SCC, andPS0to1,andwhohavecontraindicationstoordeclineimmunotherapyandnotdeemedcandidatesforplatinum-based therapy

2020 Cancer Care Ontario

25. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

effectiveness 16 Costs in the model 21 Cost-effectiveness results 22 Innovation 24 Discount rate 24 End of life 25 Cancer Drugs Fund 26 Other factors 27 4 Implementation 29 5 Appraisal committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559) © NICE 2019. All rights reserved. Subject to Notice of rights (https (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 311 1 Recommendations Recommendations 1.1 Axicabtagene ciloleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed. 1.2 This recommendation is not intended to affect both treatment in preparation

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

26. Is diarrhea an adverse event of the second generation of hormonal therapy in castration resistant prostate cancer? Data from a literature based meta-analysis

Is diarrhea an adverse event of the second generation of hormonal therapy in castration resistant prostate cancer? Data from a literature based meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2019 PROSPERO

27. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy MASCC=ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy Rajesh V. Lalla, DDS, PhD 1 ; Joanne Bowen, PhD 2 ; Andrei Barasch, DMD, MDSc 3 ; Linda Elting, PhD 4 ; Joel Epstein, DMD, MSD 5 ; Dorothy M. Keefe, MD 2 ; Deborah B. McGuire, PhD, RN 6 ; Cesar Migliorati, DDS, MS, PhD 7 ; Ourania Nicolatou-Galitis, DDS, MSc, DrDent 8 ; Douglas E. Peterson, DMD (...) mucositis in patients receiving H&NRT. No guideline was possible regarding theuseoforalcareprotocolsforthetreatmentoforalmuco- sitis. In addition, no guideline was possible related to the individualuseofthefollowingmouthrinses:saline,sodium bicarbonate, mixed medication mouthwashes, calcium phosphate, and chlorhexidine in patients receiving chemo- therapy,duetoinadequateand=orconflictingevidence. 31 Growth factors and cytokines To the best of our knowledge, palifermin (keratinocyte growthfactor-1

2014 International Society for Oral Oncology

28. Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome

Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03457324 Recruitment Status

2018 Clinical Trials

29. Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients Full Text available with Trip Pro

Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients The aim was to evaluate the effects of traditional Chinese medicine (TCM) as a combination medication with adjuvant chemotherapy on postoperative early stage non-small cell lung cancer (NSCLC) patients. The 314 patients with completely resected stage IB, II or IIIA cancers were assigned into vinorelbine plus cisplatin/carboplatin (NP/NC) (control, n = 158) and NP/NC (...) with additional TCM (intervention, n = 156) groups. The primary endpoint was QOL scores; secondary endpoints were the toxicity and safety of the regimens. The NP/NC regimen caused mild (grade 1 or 2) non-hematologic toxic effects in the patients comprising vomiting (43.6%), fatigue (36.9%), pain (23%), dry mouth (27.6%) and diarrhea (7.9%). The incidence of adverse events was significantly lower in the intervention group than in the control group (0.57% vs 4.02%, P = 0.037). Transient severe (grade 3 or 4

2017 Scientific reports Controlled trial quality: uncertain

30. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine.

Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. (aCTIVE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

31. Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis

dose. Week 2 to Week 14: SC injection of tralokinumab maintenance dose. CYP substrates - non-investigational medicinal products: Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg. Drug: Tralokinumab Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation (...) Frame: From Day 1 up to Week 30 ] Presence of anti-drug antibodies (yes/no) [ Time Frame: From Day 1 up to Week 30 ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout

2018 Clinical Trials

32. Emerging Drugs for Duchenne Muscular Dystrophy

regulatory approval, a major barrier to the uptake of novel therapies for DMD is likely to be cost. Furthermore, there is the possibility for some of the medications to be used in combination, which will increase the cost further. Criteria will need to be determined to establish which patients are more likely to benefit, and to identify when a drug is no longer beneficial. Administering medication to children can be challenging. Idebenone and ataluren are orally administered and require multiple daily (...) and mortality. DMD is caused by a mutation of the dystrophin gene that results in a lack of dystrophin, a protein that is necessary for muscle cell function. The mainstays of current therapy to treat DMD are corticosteroids and assistive devices. This bulletin focuses on new and emerging drugs for DMD with completed phase IIb or phase III trials and includes ataluren (nonsense mutation suppression), eteplirsen (exon 51 skipping), and idebenone (adenosine triphosphate [ATP] modulation). Ezutromid (utrophin

2017 CADTH - Issues in Emerging Health Technologies

33. One group of drugs used to treat Crohn’s disease is unlikely to prevent relapse

condition which can affect any part of the gastrointestinal tract, causing pain, diarrhoea and weight loss. It is characterised by recurring bouts of inflammation which can be severe. Once an attack has been treated through use of corticosteroids and other medication, options to prevent relapses are limited to immunosuppressants, but each can cause serious side effects. As 5-ASAs are an effective treatment when corticosteroids are unsuitable, it was hoped that they might also be a preventive option (...) with fewer side effects. Biological drugs such as infliximab, adalimumab and vedolizumab are usually reserved in the UK for people with severe disease who respond poorly to other drug treatment. This study confirms NICE guidance and strengthens the case for using immunosuppressants such as azathioprine, mercaptopurine or methotrexate, and not 5-ASAs, for prevention of flare-ups of Crohn’s disease after medical treatment. Share your views on the research. Why was this study needed? About 115,000 people

2019 NIHR Dissemination Centre

34. Emerging Drugs for Duchenne Muscular Dystrophy

regulatory approval, a major barrier to the uptake of novel therapies for DMD is likely to be cost. Furthermore, there is the possibility for some of the medications to be used in combination, which will increase the cost further. Criteria will need to be determined to establish which patients are more likely to benefit, and to identify when a drug is no longer beneficial. Administering medication to children can be challenging. Idebenone and ataluren are orally administered and require multiple daily (...) and mortality. DMD is caused by a mutation of the dystrophin gene that results in a lack of dystrophin, a protein that is necessary for muscle cell function. The mainstays of current therapy to treat DMD are corticosteroids and assistive devices. This bulletin focuses on new and emerging drugs for DMD with completed phase IIb or phase III trials and includes ataluren (nonsense mutation suppression), eteplirsen (exon 51 skipping), and idebenone (adenosine triphosphate [ATP] modulation). Ezutromid (utrophin

2017 CADTH - Issues in Emerging Health Technologies

35. Smectite for acute infectious diarrhoea in children. Full Text available with Trip Pro

Smectite for acute infectious diarrhoea in children. As mortality secondary to acute infectious diarrhoea has decreased worldwide, the focus shifts to adjuvant therapies to lessen the burden of disease. Smectite, a medicinal clay, could offer a complementary intervention to reduce the duration of diarrhoea.To assess the effects of smectite for treating acute infectious diarrhoea in children.We searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register (...) between groups (RR 4.71, 95% CI 0.56 to 39.19; 2 studies; 128 children; low-certainty evidence). No deaths or serious adverse effects were reported.Based on low-certainty evidence, smectite used as an adjuvant to rehydration therapy may reduce the duration of diarrhoea in children with acute infectious diarrhoea by a day; may increase cure rate by day 3; and may reduce stool output, but has no effect on hospitalization rates or need for intravenous therapy.

2018 Cochrane

36. Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum

for patients with advanced or mRCC. When prescribing systemic therapy for advanced or mRCC, several key factors must be taken into account: patients are best served if the prescribing physician is an oncology specialist knowledgeable of acute and long-term toxicities, drug interactions, and monitoring of treatment and response. Patients should be managed in a multidisciplinary environment with adequate resources, including nursing care, dietary care, and pharmacy support. Patients must be evaluated (...) Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum Guideline 3-20 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum A. Finelli, N. Coakley, J. Chin, T. Flood, A. Loblaw, C. Morash, R. Shayegan, R. Siemens, and the Genitourinary Cancer Guideline Development Group Report Date: August 8, 2019 For information

2019 Cancer Care Ontario

37. Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Center at Johns Hopkins University, Baltimore, MD 6 Juravinski Cancer Centre, Hamilton, Ontario, Canada 7 University of Colorado School of Medicine, Denver, CO 8 Banner MD Anderson Cancer Center, Greeley, CO 9 Affiliated Oncologists, Chicago Ridge, IL 10 Lahey Hospital and Medical Center, Burlington, MA 11 Norton Cancer Institute, Louisville, KY 12 William Beaumont Hospital, Royal Oak, MI 13 University of Texas Southwestern Medical Center, Dallas, TX 14 Princess Margaret Cancer Centre, University (...) Health Network, Toronto, Ontario, Canada 15 City of Hope, City of Duarte, CA 16 Memorial Sloan Kettering Cancer Center, New York, NY 17 Kingston General Hospital, School of Medicine, Queen’s University, Ontario, Canada 18 Catalan Institute of Oncology, Barcelona, Spain 19 Inova Schar Cancer Institute, Falls Church, VA 20 Postgraduate Institute of Medical Education and Research, Chandigarh, India 21 Sarah Cannon Research Institute, Nashville, TN 22 Patient advocate 23 Circle of Hope for Cancer

2020 American Society of Clinical Oncology Guidelines

38. Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer

standard fractionation (45- 50.4Gy in 25-28 fractions) preoperative RT+/-CT should be offered postoperative CT in the absence of direct evidence for this is described in more detail in the Discussion section of the systematic review for preoperative therapy (Section 2. Part 1). ? Enteritis, diarrhea, bowel obstruction or perforation, and fibrosis within the pelvis are associated with RT. Delayed adverse effects from RT include radiation enteritis (4%), small bowel obstruction (5%), rectal stricture (5 (...) resection, sphincter preserving surgery, quality of life, acute toxicities, postoperative morbidity (within 30 days of surgery ), and late toxicities (>90 days after surgery). If no significant difference in the primary outcome of interest was demonstrated, secondary outcomes were examined to form conclusions. For the comparison of preoperative RT versus surgery alone, the studies using short-course treatments and therapy were not expected to downstage the tumour; therefore, circumferential radial

2019 Cancer Care Ontario

39. Enteral nutritional therapy for induction of remission in Crohn's disease. Full Text available with Trip Pro

between elemental and non-elemental diets in adverse event rates (RR 1.00, 95% CI 0.63 to 1.60; GRADE very low quality), or withdrawals due to adverse events (RR 1.29, 95% CI 0.80 to 2.09; GRADE very low quality). Common adverse events included nausea, vomiting, diarrhea and bloating.Ten trials compared EN to steroid therapy. Meta-analysis of eight trials (223 participants) demonstrated no difference in remission rates between EN and steroids. Fifty per cent (111/223) of patients in the EN group (...) 2.95, 95% CI 1.02 to 8.48; GRADE very low quality). Common adverse events reported in the EN group included heartburn, flatulence, diarrhea and vomiting, and for steroid therapy acne, moon facies, hyperglycemia, muscle weakness and hypoglycemia. The most common reason for withdrawal was inability to tolerate the EN diet.Very low quality evidence suggests that corticosteroid therapy may be more effective than EN for induction of clinical remission in adults with active CD. Very low quality evidence

2018 Cochrane

40. Eluxadoline for treating irritable bowel syndrome with diarrhoea

Evidence 6 4 Committee discussion 7 Nature of the condition 7 Current practice 7 Clinical effectiveness 9 Cost effectiveness 11 Cost-effectiveness results 15 Innovation 16 Pharmaceutical Price Regulation Scheme 2014 16 Conclusion 16 Summary of appraisal committee's key conclusions 17 5 Implementation 22 6 Appraisal committee members and NICE project team 23 Appraisal committee members 23 NICE project team 23 Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471) © NICE 2018. All (...) , and it is started in secondary care. 1.2 Stop eluxadoline at 4 weeks if there is inadequate relief of the symptoms of irritable bowel syndrome with diarrhoea. 1.3 These recommendations are not intended to affect treatment with eluxadoline that was started in the NHS before this guidance was published. Adults having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>